炎症性肠病中的免疫细胞运输与滞留:机制见解与治疗进展
肠道免疫细胞运输是炎症性肠病(IBD)发病的核心环节。抗α4β7抗体维得利珠单抗已获批,抗β7抗体etrolizumab、抗MAdCAM-1抗体ontamalimab等抗运输药物(ATAs)在研,G蛋白偶联受体15等为潜在靶点。本文综述肠道免疫细胞运输的基础研究进展,并从转化角度讨论不同药理策略。
要点
- 肠道免疫细胞运输是IBD发病的核心事件。
- 维得利珠单抗(抗α4β7)已获批,多种ATAs在研。
- ATAs对单核细胞等非淋巴细胞群运输的影响尚不清楚。
核心结论
- 肠道免疫细胞运输是IBD发病的核心事件,抗运输治疗已取得临床转化进展,但免疫细胞运输生物学及ATAs作用机制的多个方面仍不明确。
研究设计与样本
- 综述,总结肠道免疫细胞运输领域的基础科学最新进展,并从转化角度讨论不同药理方法。
主要发现
- 抗α4β7抗体维得利珠单抗已获批,抗β7抗体etrolizumab和抗MAdCAM-1抗体ontamalimab等ATAs正在研发中。
- G蛋白偶联受体15被确定为潜在未来靶点。
- ATAs对单核细胞等非淋巴细胞群运输的影响以及这些疗法对免疫细胞亚群作用的精确差异仍不清楚。
临床怎么用
- 原文未据此给出推荐。
局限性
- 免疫细胞运输生物学及ATAs作用机制的多个方面仍不明确。
- 这些化合物对单核细胞等非淋巴细胞群运输的影响尚不清楚。
- 这些疗法对免疫细胞亚群作用的精确差异尚不清楚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intestinal immune cell trafficking has been identified as a central event in the pathogenesis of inflammatory bowel diseases (IBD). Intensive research on different aspects of the immune mechanisms controlling and controlled by T cell trafficking and retention has led to the approval of the anti-α4β7 antibody vedolizumab, the ongoing development of a number of further anti-trafficking agents (ATAs) such as the anti-β7 antibody etrolizumab or the anti-MAdCAM-1 antibody ontamalimab and the identification of potential future targets like G-protein coupled receptor 15. However, several aspects of the biology of immune cell trafficking and regarding the mechanism of action of ATAs are still unclear, for example, which impact these compounds have on the trafficking of non-lymphocyte populations like monocytes and how precisely these therapies differ with regard to their effect on immune cell subpopulations. This review will summarise recent advances of basic science in the field of intestinal immune cell trafficking and discuss these findings with regard to different pharmacological approaches from a translational perspective.
引用
- Zundler S, Becker E, Schulze LL, et al. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut. 2019. PMID: 31127023. doi:10.1136/gutjnl-2018-317977
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。